Ophthalmology 360?

Gene therapy is emerging as a promising treatment for genetic retinal disorders, with research demonstrating significant progress in animal models and early clinical trials, according to a presentation at the 50th Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus. Read more: https://lnkd.in/ezgyrpVp #EarlyOnsetCataracts #Cataracts #GeneTherapy #Genetics

Incredible day on the Hill yesterday with National Alliance for Eye and Vision Research (NAEVR) and Thomas V Johnson! We spoke about glaucoma from the perspective of the patient and clinician/researcher. Dr Johnson shared some of his incredible research on regrowing retinal ganglion cells. We also had the opportunity to meet with several Congressional offices to discuss the importance of continued funding for eye and vision research. Patients coupled with clinicians/researchers make magic happen. Separately we make a difference - together we create change!

In the latest episode of The Ophthalmic Project, Mark Dlugoss speaks with Sean Ianchulev MD MPH, of Iantrek about the company’s latest advancements in glaucoma care. In this clip, Dr. Ianchulev talks about how innovation can be daunting and uncertain, but how pushing forward and pivoting where needed helps move new ideas forward. Watch the complete video here: https://lnkd.in/eYtq-JNN #Innovation #IntravitrealInjections #Ophthalmic

Beautiful day here in D.C. ???? Excited to speak at the National Alliance for Eye and Vision Research (NAEVR) Glaucoma Congressional Briefing today with Thomas V Johnson! ??There is power when patients are coupled with researchers and clinicians to speak at events. Let’s do this!

The combination of topical ivermectin 1% and intense pulsed light (IPL) therapy significantly improves dry eye disease (DED) caused by demodex blepharitis, with notable reductions in blepharitis and meibomian gland dysfunction, according to a study. Read more: https://lnkd.in/eTaNzaku #DryEyeDisease #DemodexBlepharitis #MeibomianGlandDysfunction

During a session at the American Glaucoma Society Annual Meeting, titled “The Future Starts Now – What’s Next in the Supraciliary Space and Interventional Drug Delivery,” Analisa Arosemena, MD, of the Correct Vision Laser Institute, spoke about the use of travoprost intracameral implant (iDose?) for glaucoma management. Read more: https://lnkd.in/eg7WcbYv #Glaucoma #MIGS #GlaucomaSurgery

Lotilaner ophthalmic solution (0.25%) is a safe and effective treatment for Demodex blepharitis, significantly reducing collarettes, mite density, and erythema over 6 weeks with minimal adverse effects and high patient comfort, according to a pooled analysis of 2 pivotal clinical trials. Read more here: https://lnkd.in/eAE6t_WC #DryEye #DryEyeDisease #DemodexBlepharitis

?? One week to go! I’ll be speaking with Thomas V Johnson at the Glaucoma Congressional Briefing hosted by National Alliance for Eye and Vision Research (NAEVR) in Washington, D.C. As a severe glaucoma patient, I’m honored to share my story and advocate for greater awareness about glaucoma. It is the leading cause of irreversible blindness, affecting over 4 million Americans. ?? Date: March 18th?? Time: 12-1 PM??? Location: Rayburn Room 2045 This event will highlight the critical need for early detection, innovative treatments, and sustained research to reduce healthcare costs and preserve vision for millions. A special thank you to our sponsors—ARVO, AbbVie, Johnson & Johnson, and Théa—for making this event possible. Let’s work together to shine a light on glaucoma and vision research! ?? #GlaucomaAwareness #VisionResearch #PatientAdvocacy #CongressionalBriefing #EyeHealth

Although pseudophakic donor grafts pose greater challenges during preparation and have longer recovery times compared to phakic and scarred stromal grafts, they can still provide comparable outcomes in Descemet membrane endothelial keratoplasty (DMEK) when complications do not occur, according to a study. Read more: https://lnkd.in/g8FPF3Zu #OcularSurface #OrganDonor #NationalEyeDonorMonth

A secondary analysis of data from the Age-Related Eye Disease Studies (AREDS and AREDS2) found that the progression of geographic atrophy (GA) in age-related macular degeneration is strongly linked to a decline in best-corrected visual acuity (BCVA) over 4 years. Read more: https://ow.ly/F8go50VcThF #GeographicAtrophy #AMD #VisualAcuity #MacularDegeneration